Loading
A phase 2 trial of Mirvetuximab soravtansine, Bevacizumab, Carboplatin in ovarian cancer, run by AbbVie, now recruiting.
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer is a phase 2 interventional study registered as NCT07059845 by AbbVie, with 400 participants planned, started 2025-11-13 and due to reach its primary completion in 2029-01. Interventions recorded: Mirvetuximab Soravtansine, Bevacizumab, Carboplatin. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Carboplatin, Antibody-drug conjugate (ADC).
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin, Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, Carboplatin, Antibody-drug conjugate (ADC), Ovarian cancer.